Asbestos ban fails to halt rising mesothelioma cases in Singapore
For 35 years, asbestos has been banned in Singapore, yet its deadly impact lingers. Despite the prohibition, the number of malignant mesothelioma cases—a cancer caused [more…]
Category: Health & Fitness
AstraZeneca and CSPC join forces to combat high cholesterol
In a move to strengthen its cardiovascular treatment portfolio, AstraZeneca announced a partnership with CSPC Pharmaceutical Group that could reach a staggering $1.92 billion. This [more…]
Novo Nordisk’s Wegovy approved in China, faces patent challenges and competition
Novo Nordisk’s weight-loss drug Wegovy has received the green light in China, targeting the world’s second-largest economy and the country with the highest number of [more…]
Kobayashi Pharmaceutical links health issues to blue mold compound in Beni Kōji supplements
In a surprising turn, Kobayashi Pharmaceutical, the embattled drugmaker at the center of a health scandal involving its beni kōji (red yeast rice) dietary supplements, [more…]
Thailand’s consulate in Osaka issues health advisory following measles cases in Japan
The Thai consulate in Osaka has issued an unusual health advisory for Thai nationals residing or traveling in Osaka, Japan, following the confirmation of measles [more…]
Celltrion celebrates U.S. launch of Zymfentra, offering patients new hope
Celltrion, the pioneering Korean biopharmaceuticals firm, has made a significant stride in the US market with the launch of its groundbreaking autoimmune disease treatment, Zymfentra. [more…]
Opill, the first over-the-counter oral contraceptive, hits shelves in the U.S.
The arrival of Opill, the first over-the-counter oral contraceptive in the United States, marks a significant milestone in reproductive health accessibility. With a manufacturer’s suggested [more…]
Viking Therapeutics’ VK2735 demonstrates promising results in weight loss
Viking Therapeutics surged approximately 80% on Tuesday following the announcement of promising results from its mid-stage trial of an experimental weight loss drug. The drug, [more…]
Eisai’s Alzheimer’s drug Leqembi set for China rollout
Eisai plans to introduce its groundbreaking Alzheimer’s drug, Leqembi, to 1,500 people in China this year, with expectations of significant growth in 2025 as diagnosis [more…]
Japan’s first Mpox death sheds light on immunocompromised vulnerability
In a sobering turn of events, Japan has reported its first death from mpox, a viral disease that has been causing concern since its first [more…]
